Insurance companies deny PET scans more often than many patients and physicians expect, and the reasons almost always trace back to a gap between what the ordering doctor considers necessary and what the insurer’s written coverage criteria demand. The most common triggers include missing prior authorization, incomplete clinical documentation, skipping prerequisite imaging, exceeding frequency limits, or requesting the scan for an indication the insurer considers unproven. Knowing exactly where these denials originate puts you in a better position to prevent or fight them.
How Prior Authorization Controls Access to PET Scans
Most insurers require prior authorization before they will pay for a PET scan. Your doctor’s office must submit a request explaining why the scan is needed and receive approval before the appointment takes place. If the scan happens without that approval, the claim will almost certainly be denied regardless of how appropriate it was.
The original idea behind prior authorization was simple: make sure expensive tests line up with evidence-based guidelines and reduce unnecessary spending. In practice, the process has become a heavy administrative burden. Oncologists and other specialists routinely spend hours on paperwork and phone calls to get scans approved, and initial denials are common enough that peer-to-peer reviews, where the ordering physician argues the case directly to the insurer’s medical reviewer, have become a routine part of the workflow.1American Society of Clinical Oncology Educational Book. Impact of Prior Authorization on Patient Access to Cancer Care PET scans are especially likely to trigger this process because they cost several thousand dollars and insurers classify them as advanced diagnostic imaging alongside MRI and CT, setting a correspondingly higher bar for approval than a standard X-ray or ultrasound.
Radiology Benefit Managers as Gatekeepers
Many commercial insurance plans don’t handle PET scan authorizations in-house. Instead, they contract with radiology benefit management companies, or RBMs, which operate call centers dedicated to reviewing imaging requests. When your doctor’s office calls to authorize a PET scan, the voice on the other end often belongs to an RBM rather than your insurer.
RBMs use proprietary clinical guidelines to decide whether a scan meets approval criteria. Those guidelines may differ from the criteria published by professional medical societies or used by Medicare, which creates confusion. A scan that one RBM approves might be denied by another, even for the same diagnosis, because the internal algorithms and evidence thresholds vary. These companies emerged specifically to slow rapid growth in advanced imaging utilization, and prior authorization is their primary tool.2Journal of the American College of Radiology. A Prior Authorization Program of a Radiology Benefits Management Company and How It Affected Utilization of Advanced Diagnostic Imaging
The practical upshot is that your doctor may need to tailor the authorization request to the specific RBM’s criteria rather than simply documenting clinical need in general terms. Knowing which RBM your insurer uses, and what documentation it expects, can be the difference between approval and denial.
Specific Reasons a PET Scan Gets Denied
Denials don’t come out of thin air. They cluster around a handful of scenarios that recur across insurers and diagnoses:
- Medical necessity not established: The insurer or RBM concludes the clinical scenario doesn’t meet their criteria for when a PET scan is appropriate. Ordering a PET to evaluate a very small lung nodule, for instance, or for a cancer type where PET is not part of standard staging guidelines, can prompt this.
- Incomplete documentation: The referring physician’s office didn’t include pathology reports, prior imaging results, or clinical notes demonstrating why the PET is needed. Even a clearly warranted scan can be denied if the request arrives as a bare-bones form without supporting records.
- Prerequisite imaging not done: Many payers require a CT or MRI before they’ll approve a PET scan. If the workup skipped straight to PET, the insurer may deny the request on the grounds that less expensive imaging should have been tried first.
- Frequency limits exceeded: Some insurers cap the number of PET scans they’ll cover in a given period. Medicare has historically limited post-treatment surveillance PET scans, with additional scans requiring individual clinical justification. If your scan exceeds the cap without documented reasoning, expect a denial.
- Off-label or investigational indication: PET scans using newer tracers, or for conditions where the evidence base is still developing, may be classified as experimental. This has been a particularly thorny issue in neurology, as discussed below.
- Out-of-network facility or tracer: The scan was performed at a facility not contracted with your plan, or the specific radiotracer used wasn’t on the insurer’s approved list.
Documentation gaps are probably the most fixable of these. If your doctor’s office submits a request accompanied by relevant imaging, biopsy results, and a clinical note explaining how the PET would change your treatment plan, the chances of approval improve considerably.
Why Coverage Differs by Diagnosis
Insurers don’t treat PET scans the same across all medical specialties. In oncology, PET/CT is broadly accepted for staging, restaging, and monitoring treatment response in many cancer types, and coverage is relatively generous, though still subject to prior authorization. In cardiology, PET is used to assess blood flow and detect inflammation, but coverage criteria can be tighter depending on the clinical question. And in neurology, coverage has been the most contentious of all.
For years, Medicare covered amyloid PET imaging for Alzheimer’s disease only under a special “coverage with evidence development” policy, meaning it would pay for the scan only when patients were enrolled in approved clinical studies. This effectively blocked routine clinical use even as neurologists increasingly relied on the scans for diagnosis. In October 2023, Medicare ended that restriction and allowed its regional administrative contractors to make their own coverage decisions. The result was striking variation: in the first full quarter after the policy changed, adjusted PET scan rates among people with cognitive impairment ranged from 31 per 100,000 beneficiaries in one region to 613 in another.3JAMA Network. β-Amyloid Positron Emission Tomography Use Across Medicare Administrative Contractor Regions
That kind of geographic lottery highlights an underappreciated reality: even within the same national insurance program, PET scan coverage can depend heavily on where you live, because local administrators interpret clinical evidence differently.
Medicare’s decisions also shape the broader market. Private insurers frequently model their PET coverage policies on Medicare’s national coverage determinations. When Medicare restricts a PET indication, commercial plans often follow; when Medicare broadens coverage, private plans tend to loosen their criteria, sometimes with a lag of months or years.4Current Cardiovascular Risk Reports. Regulatory Agencies and PET/CT Imaging in the Clinic So a Medicare policy change for amyloid PET or a newer tracer like PSMA PET for prostate cancer can eventually ripple out to millions of commercially insured patients as well.
What Actually Happens When Your PET Scan Is Denied
A denial is not just a billing headache. It can change the trajectory of your care in concrete ways. When coverage is refused, one of several things typically follows.
The scan simply doesn’t get done, and your doctor proceeds with less complete information. In a study of bladder cancer patients being evaluated for chemotherapy response, insurance denial was identified as one of the reasons patients never received the PET/CT scan their treatment team had planned.5Clinical Genitourinary Cancer. FDG-PET/CT for Assessing the Response to Neoadjuvant Chemotherapy in Bladder Cancer Patients More broadly, research on prior authorization in oncology has found that patients denied coverage for recommended tests or treatments are commonly pushed toward second-choice options that may be less effective or harder to tolerate, or they end up absorbing substantial out-of-pocket costs themselves.1American Society of Clinical Oncology Educational Book. Impact of Prior Authorization on Patient Access to Cancer Care
Then there’s the delay factor. Even when a denial is eventually overturned on appeal, the process takes days to weeks. For someone with an aggressive cancer where treatment decisions hinge on accurate staging, or for a patient awaiting a PET-guided biopsy, that delay can matter clinically. It’s one of the harder aspects of the system to measure but one of the most commonly reported frustrations among oncologists navigating prior authorization.
How Appeals Work and Whether They Succeed
If your PET scan is denied, you have the right to appeal, and the effort is usually worthwhile. The typical first step is a peer-to-peer review, where your ordering physician speaks directly with the insurer’s medical director to argue why the scan meets medical necessity criteria. This is often the fastest route to overturning a denial. The physician can present clinical context that the original paperwork may not have captured: a rapidly growing mass, ambiguous CT findings, a situation where the PET result will determine whether surgery proceeds.
If the peer-to-peer doesn’t resolve the issue, a formal written appeal follows. This generally includes detailed medical records, imaging guidelines from professional societies, and a letter from the treating physician explaining the clinical reasoning. Many successful appeals reference published evidence showing that PET scans frequently change management decisions.
One revealing finding from research on radiology prior authorization deserves mention here. When a large insurer experimentally eliminated the denial provision from its imaging authorization program, utilization didn’t go up. It actually decreased slightly compared to a control group that kept the denial option in place.6Journal of the American College of Radiology. The Effect of a No-Denial Policy on Imaging Utilization The implication is that much of the utilization-management effect comes from the process of requiring authorization itself, the friction of the phone call and the paperwork, rather than from the actual denials. For you as a patient, this suggests the denial you received may have less to do with a genuine clinical judgment that the scan was inappropriate and more to do with the structural incentives baked into the PA system. That’s a reason not to take a denial at face value.
If internal appeals are exhausted and the insurer still refuses, most states allow you to request an external review by an independent third party. The rules vary by state and plan type, but external reviews are generally binding on the insurer if the reviewer sides with you. Your state’s department of insurance can explain the process, and many cancer centers have patient advocates or financial counselors who help navigate it.
Evidence That PET Scans Change Treatment Decisions
One of the core frustrations surrounding PET scan denials is that there’s strong real-world evidence these scans meaningfully alter the course of care. A large German oncology registry found that PET/CT changed clinical management in about 37% of cases. The most common shift, accounting for roughly 30% of cases, was from a plan of no active treatment to active treatment after the scan revealed findings that demanded intervention. The scan also slashed the need for additional imaging from about two-thirds of cases to just 6%, and it allowed physicians to cancel planned invasive procedures in nearly three out of four cases where such procedures had been scheduled.7European Journal of Nuclear Medicine and Molecular Imaging. Practice-based evidence for the clinical benefit of PET/CT-results of the first oncologic PET/CT registry in Germany
In about one in five cases, the scan changed the treatment goal itself, more often shifting from curative to palliative intent than the other way around. That’s a sobering finding, but it underscores the point: without the PET scan, some patients would have undergone aggressive treatments unlikely to help them, while others might have missed their window for curative therapy. Either error has real consequences. When you or your physician are building an appeal, this kind of evidence can be powerful ammunition for arguing that the scan will change your care, not merely confirm what’s already known.
Emerging Indications and the Coverage Gap
The coverage framework for PET scans is structurally conservative, and that conservatism hits hardest when the scan is being used for something relatively new. New PET tracers are developed regularly, targeting everything from prostate cancer recurrence to cardiac sarcoidosis to neuroendocrine tumors. Each new application needs to accumulate published clinical evidence before insurers will cover it routinely, and the lag between when clinicians start using a tracer and when payers catch up can stretch for years.
During that gap, patients whose doctors believe a newer PET application would meaningfully help their care sit in a frustrating gray zone. The scan exists, the clinical rationale is sound, but the insurer’s criteria haven’t been updated. Denials for these indications are nearly automatic, and appeals require the physician to build a one-off argument that the evidence supports this particular use, an exhausting process that many physicians cannot sustain for every patient who needs it.
The amyloid PET story in Alzheimer’s disease is the highest-profile example, but similar dynamics play out with newer oncology tracers. PSMA PET for prostate cancer, for instance, gained rapid clinical adoption after FDA approval of the tracers, but commercial coverage policies lagged behind in many plans, leaving patients caught between what their oncologist recommended and what their insurer would pay for. If you find yourself in this situation, asking your specialist whether access through a clinical trial or institutional protocol is possible can sometimes bypass the coverage question entirely. Academic medical centers, in particular, often have mechanisms to provide newer PET applications outside the standard insurance pathway.
Steps You Can Take Before the Scan Is Ordered
Prevention is easier than appeals. A few practical moves can reduce the risk of a denial before it happens:
- Ask about PA upfront: Before scheduling the PET scan, confirm that your doctor’s office has submitted the prior authorization request and received approval. Don’t assume it was done automatically.
- Check your plan’s criteria: Call your insurer or check the plan documents for imaging-specific coverage rules. Some plans publish their medical necessity criteria online. Knowing the standard in advance lets your doctor tailor the request.
- Ensure prerequisite imaging is documented: If your plan requires a CT or MRI before approving a PET scan, make sure those results are included in the authorization package.
- Request the denial in writing: If a denial comes through, get the specific reason in writing. A denial letter that says “not medically necessary” without further explanation gives you less to work with than one citing a specific guideline criterion you can address directly.
- Involve your doctor early: Physicians who personally engage with the appeal, especially through a peer-to-peer call, have more success than offices that rely solely on written submissions. Let your doctor know you’re willing to advocate alongside them.
None of this guarantees approval, and there are genuine cases where a PET scan isn’t the right next step. But in situations where the clinical need is clear and the denial stems from a paperwork gap or a criteria mismatch, a proactive approach can save weeks of back-and-forth and keep your care on track.